Brivaracetam: A Comprehensive Overview of its Nootropic Properties
Brivaracetam (trade name: Briviact) is a nootropic drug used to treat epilepsy and other neurological disorders. It is a derivative of the racetam family of drugs, which are known for their cognitive-enhancing effects. Brivaracetam is also known by its chemical name, BRV-A, and its generic name, brivaracetam.
Brivaracetam is a synthetic drug that is structurally similar to piracetam, the first racetam drug to be developed. It is a white to off-white powder that is soluble in water and has a molecular weight of 253.3 g/mol. Brivaracetam is metabolized in the liver and has a half-life of approximately 8-10 hours.
Brivaracetam is used to treat epilepsy and other neurological disorders. It works by increasing the levels of the neurotransmitter GABA in the brain, which helps to reduce seizures. It is also thought to have neuroprotective effects, which may help to protect the brain from damage caused by seizures.
- Reduces seizures in people with epilepsy
- May have neuroprotective effects
- Improves cognitive function
- Improves mood and reduces anxiety
- Improves memory and learning
Possible Negative Effects
- Weight gain
The recommended starting dose of brivaracetam is 50 mg twice daily. The dose can be increased up to 200 mg twice daily, depending on the individual's response. It is important to take brivaracetam exactly as prescribed by your doctor.
Brivaracetam was first developed in the early 2000s by UCB Pharma, a Belgian pharmaceutical company. It was approved by the US Food and Drug Administration (FDA) in 2016 for the treatment of partial-onset seizures in adults and children aged four years and older. Since then, it has become a popular treatment for epilepsy and other neurological disorders.
Brivaracetam has also been studied for its potential nootropic effects. Studies have shown that it can improve cognitive function, memory, and learning, as well as reduce anxiety and improve mood. These effects make it a promising treatment for a variety of neurological disorders.